Akorn, Inc. And Serum Institute of India, Ltd. Announce The Signing Of A Definitive Development And Exclusive Distribution Agreement For Rabies Monoclonal Antibody
Published: Nov 08, 2006
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (AMEX:AKN) and Serum Institute of India, Ltd. today announced that they have entered into a Definitive Development and Exclusive Distribution Agreement for Rabies monoclonal antibody. The Agreement finalizes a previously executed Memorandum of Understanding dated April 4, 2006 with respect to both companies collaboration in developing and distributing monoclonal antibody drugs. The term of the Agreement is ten years following the first commercial sale of products.